Argus raises Salesforce stock price target on guidance increase

Oil jumped 3% on renewed Hormuz supply-disruption concerns from U.S. strikes on Iran, but the company-specific news is bullish for Salesforce: Argus raised its CRM price target to $300 from $290 (Buy) after Salesforce increased full-year guidance for a second time and guided to revenue acceleration in fiscal 2H 2027. Salesforce reported Q1 FY2027 revenue +11% and non-GAAP operating income +10% with a 77% gross margin, raised its FY2027 non-GAAP EPS estimate to $16.68 from $14.41, and announced a new partnership with Anthropic tied to enterprise agentic AI integration. Multiple analysts lifted targets (Truist to $300, TD Cowen to $280, Monness to $266) after earnings beat and improved growth signals, with the stock noted as undervalued on a P/E of 24 and PEG of 0.38.

Analysis

CRM is trading less like a mature app vendor and more like a scarce AI-enabled operating system for enterprise workflows, which is why the market keeps rewarding every incremental proof point with multiple expansion. The key mechanism is not the partnership headline itself; it is the ability to use distribution and installed base to turn AI features into higher ACV, lower churn, and a longer monetization runway than standalone model providers can achieve.

The second-order winner is the vendor ecosystem around CRM, especially hyperscalers and model partners that get embedded into enterprise workflows without bearing customer acquisition costs. The hidden loser is the broader SaaS cohort: if CRM proves it can upsell AI while preserving margins, peers such as WDAY, HUBS, and even adjacent workflow software will face a higher bar for growth justification and a tougher pricing conversation with customers.

The main risk is that investors are underwriting future acceleration that sits several quarters out, while AI usage can raise inference and support costs before it clearly lifts revenue. The thesis is falsified if next quarters show cRPO growth stalling, incremental AI monetization is not visible in billings/deferred revenue, or gross margin starts drifting down as AI attach increases. Near term, the stock can keep drifting higher on estimate revisions; over 6-18 months, the debate becomes whether AI is a real profit pool or just a feature that prevents share loss.

Key Decisions for Investors

• Go long CRM versus short IGV for 1-3 months to isolate relative outperformance from earnings revisions; use a close below the post-upgrade breakout level or a guidance reset as the stop.
• Buy a 3-6 month CRM call spread financed with an out-of-the-money short call to express upside from continued analyst target raises while limiting downside if the AI monetization story stalls.
• Pair long CRM / short WDAY over 6 months as a relative value expression on enterprise AI monetization; thesis works if CRM converts AI into billings and WDAY remains valuation-sensitive.
• Set a hard watch item on next quarter cRPO and gross margin: if cRPO growth slips below low-teens or margin trends down, cut exposure because the market is paying for acceleration, not just execution.